千红制药(002550) - 2015 Q3 - 季度财报

Financial Performance - Net profit attributable to shareholders decreased by 2.91% to CNY 68,187,040.20 for the reporting period[9] - Operating revenue decreased by 7.00% to CNY 191,490,982.21 for the reporting period[9] - Basic earnings per share decreased by 9.09% to CNY 0.10 for the reporting period[9] - The estimated net profit attributable to shareholders of the listed company for 2015 is expected to increase by 5% to 20%, ranging from 257.29 million to 294.04 million yuan[22] Assets and Liabilities - Total assets increased by 13.91% to CNY 2,632,202,667.94 compared to the end of the previous year[9] - Prepayments increased by 123.49% compared to the beginning of the period, mainly due to increased advance payments[16] - Construction in progress increased by 62.31% compared to the beginning of the period, attributed to increased investment in ongoing projects[16] - Accounts payable decreased by 85.10% compared to the beginning of the period, primarily due to payments made for outstanding goods[16] - Other current liabilities decreased by 94.11% compared to the beginning of the period, mainly due to a reduction in unpaid market development expenses[17] - Long-term borrowings decreased by 27 million yuan compared to the beginning of the period, primarily due to a decrease in unpaid bank loans over one year[17] - Short-term borrowings increased by 280 million yuan compared to the beginning of the period, mainly due to an increase in bank loans[17] - Deferred income increased by 197.87% compared to the beginning of the period, mainly due to receiving infrastructure subsidy payments[17] Cash Flow - Cash flow from operating activities increased by 22.17% to CNY 271,782,897.13 year-to-date[9] - Net cash flow from financing activities increased by 420.07% compared to the same period last year, mainly due to an increase in bank loans[18] Operating Costs and Income - Operating costs decreased by 36.84% compared to the same period last year, primarily due to a decrease in the purchase price of heparin sodium crude products[17] - Asset impairment losses increased by 82.49% compared to the same period last year, mainly due to a decrease in inventory impairment write-offs[17] - Investment income increased by 344,100 yuan compared to the same period last year, mainly due to increased income from the sale of Minsheng Jia Yin money market funds[17] - The decrease in operating income from non-operating activities was 44.83% compared to the same period last year, mainly due to a reduction in government subsidies[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 50,230[12] - The largest shareholder, Wang Yaofang, holds 22.80% of the shares, totaling 145,944,000 shares[12]